Pembrolizumab provides long‐term survival benefits in advanced non‐small cell lung cancer: The 5‐year outcomes of the KEYNOTE‐024 trial
oleh: Fengtan Li, Xifeng Dong
| Format: | Article |
|---|---|
| Diterbitkan: | Wiley 2021-12-01 |
Deskripsi
No description available for this item.